BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 25960594)

  • 1. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
    Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
    Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
    Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
    Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The utility of NT-proBNP and various echocardiographic methods in the determination of doxorubicin induced subclinical late cardiotoxicity.
    Yildirim A; Tunaoglu FS; Kambur K; Pinarli FG
    Kardiol Pol; 2013; 71(1):40-6. PubMed ID: 23348532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines.
    Germanakis I; Kalmanti M; Parthenakis F; Nikitovic D; Stiakaki E; Patrianakos A; Vardas PE
    Int J Cardiol; 2006 Apr; 108(2):212-5. PubMed ID: 16290101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
    Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
    Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
    van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
    Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.
    Ylänen K; Poutanen T; Savukoski T; Eerola A; Vettenranta K
    Acta Paediatr; 2015 Mar; 104(3):313-9. PubMed ID: 25393922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
    Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cardiac effects of treatment for childhood leukemia.
    Urbanova D; Urban L; Simkova I; Danova K; Mikuskova E; Mladosievicova B
    Neoplasma; 2010; 57(2):179-83. PubMed ID: 20099983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.
    Pongprot Y; Sittiwangkul R; Charoenkwan P; Silvilairat S
    J Pediatr Hematol Oncol; 2012 Nov; 34(8):589-95. PubMed ID: 23018571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines.
    Mladosievicova B; Urbanova D; Radvanska E; Slavkovsky P; Simkova I
    J Exp Clin Cancer Res; 2012 Oct; 31(1):86. PubMed ID: 23057994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
    Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
    Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy.
    Soker M; Kervancioglu M
    Saudi Med J; 2005 Aug; 26(8):1197-202. PubMed ID: 16127512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Values of high sensitive troponin T in long-term survivors of childhood cancer treated with anthracyclines.
    Pourier MS; Kapusta L; van Gennip A; Bökkerink JP; Loonen J; Bellersen L; Mavinkurve-Groothuis AM
    Clin Chim Acta; 2015 Feb; 441():29-32. PubMed ID: 25512165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
    Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.